Drug Trial Radar · NCT00092989
Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)
Last checked: Nov 20, 2026Latest source record: Aug 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
650
Actual
Start
Jul 2004
Primary completion
Mar 2007
Study completion Mar 2007
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate improved results of treatment for patients entering an emergency department with asthma attacks when given an investigational IV administration of an approved drug (MK-0476, montelukast sodium) in addition to approved standard treatment.
Conditions
- Asthma
Interventions
montelukast sodiumDrug
Duration of Treatment: 1 dose
placeboDrug
Duration of Treatment: 1 dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement in forced expiratory volume in 1 second [FEV1] within the first 60 minutes after administrationTime frame: within the first 60 minutes after administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.